Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIO 300 Oral Powder is a solid oral formulation of nanocrystalline genistein, an isoflavone that enhances cellular DNA damage response pathways and exerts radioprotective, anti-inflammatory, and antifibrotic effects, being developed primarily as a medical countermeasure to prevent acute radiation syndrome and mitigate delayed radiation-induced lung injury and fibrosis in military and civilian settings.[1] Developed as a more bioavailable, shelf-stable amorphous dispersion of the same active pharmaceutical ingredient used in the earlier BIO 300 oral suspension, the powder formulation is designed for convenient tablet or capsule dosing while maintaining systemic genistein exposures associated with protection of lung tissue during or after radiation and potentially in post-viral lung injury such as COVID-19–related fibrosis.[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BIO 300 Oral Powder.